The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Barclays' Matt Miksic targets $143 for Abbott, implying 35% upside, while Exact Sciences acquisition costs masked five consecutive adjusted EPS beats.

Abbott trades at 19x forward earnings with 54 straight dividend hikes; Boston Scientific carries 38% implied upside after collapsing 51% year to date.

CEO Robert Ford expects accelerating sales and earnings growth in H2 2026, with management raising full-year adjusted EPS guidance to a range of $5.45 to $5.60.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks โ€” and Abbott Laboratories didn't make the cut. Grab the names FREE today.

Abbott Laboratories (NYSE:ABT) currently trades at $105.70, while the Street's consensus price target sits at $118.42, implying roughly 12% of upside. Barclays analyst Matt Miksic carries the highest active target at $143, translating to about 35% in gains from here.

Abbott is a diversified healthcare giant with a market cap near $182.9 billion, operating across medical devices, diagnostics, established pharmaceuticals, and nutrition. Wall Street prizes the company for its FreeStyle Libre continuous glucose monitor franchise, structural heart pipeline, and a dividend record spanning 54 consecutive years of increases.

The gap matters because the S&P 500 is up 9.55% year to date while Abbott has declined.

The catalyst was the $21 billion Exact Sciences acquisition that closed on March 23, 2026, creating earnings distortion. GAAP EPS in Q2 collapsed to $0.53 from $1.01 from $658 million in intangible amortization, $299 million in interest expense, and a $385 million legal reserve a year earlier. Quarterly earnings growth on a reported basis came in at negative 47.5%.

By the time Abbott filed Q2 results, shares had fallen from $127.12 Q3 2025 filing price to $89.79. Underneath the GAAP mess, adjusted EPS beat at $1.31 versus a $1.28 consensus, a fifth straight beat. Revenue reached $12.59 billion. The market focused on optics rather than operating trends.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks โ€” and Abbott Laboratories didn't make the cut. Grab the names FREE today.

Segment weakness reinforced caution. Nutrition fell 3.1%, U.S. Structural Heart dropped 9.8%, and rapid and molecular diagnostics slid 7.3% on soft respiratory season. Abbott is now down 14.08% year to date and 14.3% over the trailing year.

The bull case rests on adjusted earnings power that GAAP figures obscure. Management raised full-year adjusted EPS guidance to $5.45 to $5.60 and reaffirmed 6.5% to 7.5% comparable sales growth, both despite roughly $0.20 dilution tied to the Exact Sciences deal. CEO Robert Ford said the company expects "accelerating sales and earnings growth in the second half of the year."

Miksic's $143 target is anchored on FreeStyle Libre 3 adoption, gross margin expansion in medical devices, and steady growth from Navitor and TriClip in structural heart. Continuous glucose monitor sales hit $2.19 billion in Q2, up 10.5%, and Cologuard is running at mid-teens growth after the American Cancer Society reaffirmed it as preferred screening.

Across 28 analysts, coverage breaks down as:

Strong Buy: 4

Buy: 17

Hold: 7

Sell: 0

Recent revisions have leaned lower even where Buy ratings stuck. UBS trimmed its target to $125 from $135 in late July while maintaining Buy. That pattern tells you analysts still like the underlying business but expect a slower path higher.

Medtronic (NYSE:MDT) trades at $85.39, down 9.59% year to date, with an average target of $98.44 for roughly 15% upside. Coverage is split with 18 Buys against 12 Holds.

Boston Scientific (NYSE:BSX) is the outlier. Shares sit at $46.73 after a 50.99% year-to-date collapse tied to two consecutive guidance cuts. The consensus target of $64.28 implies about 38% upside, with 27 of 31 analysts rating it Buy or better.

Danaher (NYSE:DHR) trades at $194.98, down 14.46% year to date. Its $227.96 target points to about 17% upside, with 22 Buys and 4 Holds.

Boston Scientific carries the largest implied upside, but only because it fell hardest. Against a more stable peer set, Abbott's 12% consensus upside looks middle of the pack. Miksic's 35% target is what makes the story interesting.

Abbott trades at $105.70, with a $118.42 consensus target across 28 analysts. Forward P/E is 19, and the dividend yields 2.35%.

Abbott is off 14.08% year to date while the S&P 500 is up 9.55%. Over one year, Abbott is down 14.3% versus 18.19% for the index. Shares have rallied 15.48% in the past month, suggesting the worst of the reset may be behind.

The bull case works if H2 2026 delivers the acceleration management has telegraphed. That means CGM sustaining double-digit growth against Dexcom, Cologuard compounding at mid-teens, Structural Heart U.S. stabilizing, and Exact Sciences dilution rolling off into 2027. If adjusted EPS lands at the high end of the $5.45 to $5.60 range and margins expand as Miksic expects, a re-rating toward the $130s becomes reasonable.

The bear case holds if GAAP earnings pressure lingers. Nutrition remains a drag, Structural Heart is bleeding U.S. share, and legal reserves keep appearing quarterly. If the CGM category compresses on price and Exact Sciences dilution stretches beyond guidance, this becomes a value trap.

The recent 15% monthly bounce, raised guidance, and fifth straight adjusted EPS beat point to a business executing while the tape catches up. At 19 times forward earnings for a healthcare compounder with 54 years of dividend hikes, the risk-reward profile favors a longer-term horizon.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks โ€” and Abbott Laboratories didn't make the cut. Grab the names FREE today.

Contact editorial@247wallst.com for any questions or corrections.